Showing results (21-30 of 109) with videos related to
Sort By:
Pageof 11
Oncotarget|February 13, 2016
Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaLorena Incorvaia, Giuseppe Bronte, Viviana Bazan, et al.Therapeutic Advances in Medical Oncology|February 17, 2017
Progress with palbociclib in breast cancer: latest evidence and clinical considerationsAndrea Rocca, Alessio Schirone, Roberta Maltoni, et al.Cells|April 12, 2024
The Influence of Myeloid-Derived Suppressor Cell Expansion in Neuroinflammation and Neurodegenerative DiseasesLorenza Tamberi, Alessia Belloni, Armanda Pugnaloni, et al.Oncology|February 5, 2010
The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathwayAntonio Russo, Sergio Rizzo, Giuseppe Bronte, et al.Biomed Research International|October 31, 2013
Hypoxia and human genome stability: downregulation of BRCA2 expression in breast cancer cell linesDaniele Fanale, Viviana Bazan, Stefano Caruso, et al.Journal of Oncology|September 19, 2019
Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung CancerSerena De Matteis, Matteo Canale, Alberto Verlicchi, et al.Translational Lung Cancer Research|December 21, 2019
New generation anaplastic lymphoma kinase inhibitorsAngelo Delmonte, Marco Angelo Burgio, Alberto Verlicchi, et al.Critical Reviews in Oncology/Hematology|December 22, 2023
The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping reviewAlessia Belloni, Armanda Pugnaloni, Maria Rita Rippo, et al.Expert Review of Gastroenterology & Hepatology|June 25, 2014
The role of targeted therapy for gastrointestinal tumorsChristian Rolfo, Giuseppe Bronte, Giovanni Sortino, et al.Expert Opinion on Biological Therapy|October 29, 2013
Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitorChristian Rolfo, Luis E Raez, Antonio Russo, et al.Pageof 11